Sign in

    Anthony Post

    Vice President and Equity Research Analyst at BofA Securities

    Anthony Post is a Vice President and Equity Research Analyst at BofA Securities, specializing in coverage of the biotechnology and pharmaceuticals sectors with a focus on mid- to large-cap companies. He provides in-depth research on firms such as Gilead Sciences, Amgen, and Vertex Pharmaceuticals, and his published ratings and analysis are tracked by investors and industry platforms like TipRanks, where his recommendations have demonstrated moderate performance within sector peer averages. Anthony began his career in the financial industry after completing his graduate studies, previously holding analyst and associate positions at other leading institutions before joining Bank of America in the early 2020s. He holds several FINRA securities licenses, including the Series 7 and Series 63, and is recognized for his analytical rigor and sector expertise.

    Anthony Post's questions to Expedia Group (EXPE) leadership

    Anthony Post's questions to Expedia Group (EXPE) leadership • Q3 2024

    Question

    An analyst for Anthony Post asked about selling and marketing efficiency, specifically how Expedia's efficiency compares to competitors after excluding the B2B business, and whether there are long-term cost-saving opportunities in this area.

    Answer

    CFO Julie Whalen identified marketing as a significant opportunity for efficiency gains. She explained that while current investments in Vrbo and international markets mask underlying progress, the core Brand Expedia business is already demonstrating efficiencies. She stated the company is 'laser focused' on optimizing product and supply to drive more direct and repeat traffic, which will ultimately lead to greater marketing leverage across the portfolio.

    Ask Fintool Equity Research AI